推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 中醫(yī)藥是我國傳統(tǒng)醫(yī)學(xué)和傳統(tǒng)文化的瑰寶，數(shù)千年來為中華民族及世界人民做出了巨大貢獻。但同時中藥材質(zhì)量問題作為一種現(xiàn)實存在也備受矚目，多年來一直是兩會代表委員們熱議的話題。2017全國兩會期間，全國人大代表、好醫(yī)生藥業(yè)集團董事長耿福能建議：發(fā)展中醫(yī)藥產(chǎn)業(yè)，參與精準(zhǔn)扶貧。
建好中藥材“第一車間”確保中藥材質(zhì)量
耿福能認(rèn)為，近年來，國家食藥監(jiān)局雖然加大了對中藥材的質(zhì)量控制力度，但質(zhì)量安全事故仍然高發(fā)，安全隱患較大。究其原因，在于中藥材質(zhì)量的源頭存在問題，沒有中藥的“第一車間”。對此，他建議：
首先，進行中藥材種養(yǎng)殖條件資源普查，國家建立可以種養(yǎng)殖中藥材地塊數(shù)據(jù)庫。
第二，建立種質(zhì)資源數(shù)據(jù)庫，保證中藥材質(zhì)量。
第三，盡快制定實施各中藥材種養(yǎng)殖標(biāo)準(zhǔn)，大力促進中藥材質(zhì)量建設(shè)和標(biāo)準(zhǔn)認(rèn)證。
第四，建立中藥材種養(yǎng)殖基地集散地，取代農(nóng)貿(mào)市場交易。
